28RO Bulumtatug fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: Updated results from a phase I/II study
Bulumtatug Fuvedotin (BFv, 9MW2821) is a monoclonal antibody-drug conjugate that delivers MMAE to cells expressing Nectin-4. The preliminary results of our study were presented at SGO 2024, demonstrating promising antitumor activity (unconfirmed ORR: 40.54% in 37 patients) and manageable tolerability in patients with cervical cancer. Herein, we predominantly update the efficacy data.
Authors
- R. Liu
- M Zhang
- J M Chen
- R Li
- H. Yang
- Junhua Zhang (ORCID: https://orcid.org/0000-0002-8936-3822)
- G. Li
- S. Cheng
- H. Lou
- X. Li
- C. Hu
- S. Wang
- P. Wang
- H. Bu
- S. Gao
- N. Chu
- S. Shen
Institutions
- Anhui Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Bioscience Research (US)
- Fudan University Shanghai Cancer Center (CN)
- Wuhan Union Hospital (CN)
- Anhui Provincial Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Henan Cancer Hospital (CN)
- Chongqing Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Second People’s Hospital of Yibin (CN)
- Qilu Hospital of Shandong University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108054
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00